en · de · es · pt
melanotan-2-notes.peptides8425.com › News › Melanotan-2 Structure And Receptor Pharmacology — Explained

Melanotan-2 Structure And Receptor Pharmacology — Explained

By Editorial Desk · published 2025-09-22 · last reviewed 2025-10-19 · News

alpha-MSH raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Identity and Chemical Background

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms add to total mass
Molecular massAbout 1024 daltonsCalculated for the free base
Structural classCyclic heptapeptideContains D-phenylalanine and norleucine
Parent hormoneAlpha-melanocyte-stimulating hormoneEndogenous tridecapeptide of 13 residues
Receptor profileNon-selective melanocortin agonistInteracts with MC1R, MC3R, MC4R and MC5R

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Notes from published material

=== Primary and original calibrations === The agreed-upon isotopic composition of primary reference and the original calibration materials were generally not reached through interlaboratory comparison. In part this is simply because the original materials were used to the define the isotopic scales and so have no associated uncertainty. VSMOW serves as the primary reference and calibration material for the hydrogen isotope system and one of two possible scales for the oxygen isotope system, and was prepared by Harmon Craig. VSMOW2 is the replacement calibration standard and was calibrated by measurements at five selected laboratories. The isotopic composition of SLAP was reached through interlaboratory comparison. NBS-19 is the original calibration material for the carbon isotope scale made by I. Friedman, J. R. O’Neil and G. Cebula and is used to define the VPDB scale. IAEA-603 is the replacement calibration standard and was calibrated by measurements at three selected laboratories (GEOTOP-UQAM in Montreal, Canada; USGS in Reston, USA; MPI-BGC in Jena, Germany). The isotopic composition of LSVEC was reached through interlaboratory comparison. IAEA-S-1, the original calibration material for the sulfur isotope scale and still in use today, was prepared by B. W. Robinson.

==== European Union ==== In the European Union, meloxicam is licensed for other anti-inflammatory benefits including relief from both acute and chronic pain in dogs. Meloxicam is also licensed for use in horses, to relieve the pain associated with musculoskeletal disorders. 1998 (January): Meloxicam was authorised for use in cattle throughout the European Union, via a centralised marketing authorisation. 2006: The first generic meloxicam product was approved. 2024 (January): EMA issued an 'Opinion' on a change to this medicine's authorisation concerning the follow-up oral treatment after initial injectable administration in cats. This change remains as an 'Opinion', while the medication continues to be approved as usual.

=== February === 9 February – The Scottish Prison Service concludes its review of accommodating transgender prisoners, and recommends that transgender prisoners initially be accommodated according to their sex at birth while an individual assessment is carried out. 10 February – Following a legal challenge by lap dance performers and club owners, a ban on lap dancing clubs in Edinburgh, scheduled to come into force in April, is overturned by Edinburgh's Court of Session after it finds Edinburgh City Council acted illegally by voting to limit the number of sexual entertainment venues in the city from four to zero. 15 February – Nicola Sturgeon announces her resignation as First Minister of Scotland and Leader of the Scottish National Party after eight years in the role; she will stay on until her successor has been elected. 16 February – Deputy First Minister John Swinney rules himself out of the SNP leadership contest. 17 February – The Royal College of Nursing recommends its members accept a new pay offer of 6.5%. The offer from the Scottish Government also includes changes to conditions. 19 February Scottish Health Secretary Humza Yousaf and former Minister for Community Safety Ash Regan become the first two candidates to announce they will stand in the Scottish National Party leadership election. Keith Brown, the SNP's depute leader, Neil Gray, the Minister for International Development, and Màiri McAllan, the Environment Minister, all rule themselves out of the contest.

Sources: en.wikipedia.org

Further detail

Arapaima can reach lengths of more than 2 m (6 ft 7 in), in some exceptional cases even exceeding 2.6 m (8 ft 6 in) and over 100 kg (220 lb). The maximum recorded weight for the species is 200 kg (440 lb), while the longest recorded length verified was 3.07 m (10 ft 1 in). Anecdotal reports suggest that specimens as long as 4.57 m (15 ft 0 in) exist, but verification is deemed impossible, and thus considered questionable. As a result of overfishing, arapaima more than 2 m (6 ft 7 in) are seldom found in the wild. The arapaima is torpedo-shaped, with large, blackish-green scales and red markings. It is streamlined and sleek, with its dorsal and anal fins set near its tail. Arapaima scales have a mineralised, hard, outer layer with a corrugated surface under which lie several layers of collagen fibres in a Bouligand-type arrangement. In a structure similar to plywood, the fibres in each successive layer are oriented at large angles to those in the previous layer, increasing toughness. The hard, corrugated surface of the outer layer, and the tough internal collagen layers work synergistically to contribute to their ability to flex and deform while providing strength and protection—a solution that allows the fish to remain mobile while heavily armored. The arapaima has a fundamental dependence on surface air to breathe. In addition to gills, it has a modified and enlarged swim bladder, composed of lung-like tissue, which enables it to extract oxygen from the air.

== Directed panspermia == During the 1960s, Crick became concerned with the origins of the genetic code. In 1966, Crick took the place of Leslie Orgel at a meeting where Orgel was to talk about the origin of life. Crick speculated about possible stages by which an initially simple code with a few amino acid types might have evolved into the more complex code used by existing organisms. At that time, proteins were thought to be the only kind of enzyme, and ribozymes had not yet been identified. Many molecular biologists were puzzled by the problem of the origin of a protein replicating system that is as complex as that which exists in organisms currently inhabiting Earth. In the early 1970s, Crick and Orgel further speculated about the possibility that the production of living systems from molecules may have been a very rare event in the universe, but once it had developed it could be spread by intelligent life forms using space travel technology, a process they called "directed panspermia". In a retrospective article, Crick and Orgel noted that they had been unduly pessimistic about the chances of abiogenesis on Earth when they had assumed that some kind of self-replicating protein system was the molecular origin of life. In 1976, Crick addressed the origin of protein synthesis in a paper with Sydney Brenner, Aaron Klug, and George Pieczenik. In this paper, they speculate that code constraints on nucleotide sequences allow protein synthesis without the need for a ribosome.

== Release == Lost Coast was released on October 27, 2005, as a free download for owners of Half-Life 2 on Steam. Valve announced on May 30, 2007, that Lost Coast, along with Half-Life 2: Deathmatch, would be made available for free to owners of ATI Radeon cards. It was later released without charge to Nvidia graphics card owners along with Half-Life 2: Deathmatch, Peggle Extreme, and the first eleven levels of Portal. In 2024, the 20th anniversary of Half-Life 2, Valve updated Half-Life 2 to incorporate Lost Coast and other features.

Sources: en.wikipedia.org

Background from the literature

== Reactivity == Like most alkanes, hexanes typically exhibit low reactivity and are suitable solvents for reactive compounds. Commercial samples of n-hexane however often contains methylcyclopentane, which features tertiary C-H bonds, which are incompatible with some radical reactions.

== History == Thyroxine was first isolated in pure form in 1914 at the Mayo Clinic by Edward Calvin Kendall from extracts of hog thyroid glands. The hormone was synthesized in 1927 by British chemists Charles Robert Harington and George Barger.

=== Inquiries into the paranormal === Jung had an apparent interest in the paranormal and occult. For decades, he attended seances and claimed to have witnessed "parapsychic phenomena". Initially, he attributed these to psychological causes, even delivering a 1919 lecture in England for the Society for Psychical Research on "The Psychological Foundations for the belief in spirits". However, he began to "doubt whether an exclusively psychological approach can do justice to the phenomena in question" and stated that "the spirit hypothesis yields better results". Still, he retained some skepticism toward his own postulation, as he could not find material evidence of the existence of spirits. Jung's ideas about the paranormal culminated in "synchronicity". This is the idea that certain coincidences manifest in the world, have exceptionally intense meaning to observers. Such coincidences have a great effect on the observer from multiple cumulative aspects: from the immediate personal relevance of the coincidence to the observer, from the peculiarities of (the nature of, the character, novelty, curiosity of) any such coincidence; from the sheer improbability of the coincidence, having no apparent causal link (hence Jung's essay subtitle "An Acausal Connecting Principle"). Despite his own experiments failing to confirm the phenomenon he held on to the idea as an explanation for apparent ESP. In addition, he proposed it as a functional explanation for how the I-Ching worked. However, he was never clear about how synchronicity worked.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

How does melanotan-2 differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.

What is the connection to alpha-MSH?

Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

Network